
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics Inc has seen a significant increase in momentum following its inaugural R&D Day and the positive Phase 2a data released on September 8, indicating strong investor interest and confidence in the company's direction. The company's RAP-219 has demonstrated a significantly improved therapeutic window in a first-in-patient pilot study involving 30 patients with refractory focal onset epilepsy, strengthening its clinical viability. Additionally, supportive preclinical and Phase 1 human volunteer studies suggest that even a modest reduction in efficacy could still result in successful outcomes in future Phase 3 trials, potentially positioning the drug with a commercially competitive profile.
Bears say
Rapport Therapeutics Inc. faces significant challenges as its Phase 2a efficacy data, which may be overstated due to missing patient data, raises concerns about the potential effectiveness in future Phase 3 trials. The company operates in a competitive market, where even successful regulatory approvals may not guarantee a favorable commercial outcome due to the threat of competition and potential unfavorable insurance coverage. Furthermore, while there is a high unmet need in treating life-threatening seizures, these factors collectively contribute to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares